An Analysis of SARC021

June 30, 2014
Brian A. Van Tine, MD, PhD

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses the SARC021 trial, which examined TH-302 in combination with doxorubicin versus doxorubicin alone to treat patients with locally advanced unresectable or metastatic soft tissue sarcoma.

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses the SARC021 trial, which examined TH-302 in combination with doxorubicin versus doxorubicin alone to treat patients with locally advanced unresectable or metastatic soft tissue sarcoma.

Clinical Pearls:

  • TH-302 is a hypoxia-released ifosfamide that has none of the side effects found in traditional ifosfamides.
  • TH-302 appears to be well tolerated and provide patients with a better quality of life.
  • Data from this trial have the potential to change the standard of care in sarcoma, Van Tine says.